Revised Recommendations Concerning Palivizumab Prophylaxis for Respiratory Syncytial Virus (RSV)

Overview

Journal Ital J Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2015 Dec 17

PMID 26670908

Citations 35

Authors

Lina Bollani

Eugenio Baraldi

Gaetano Chirico

Andrea Dotta

Marcello Lanari

Antonello Del Vecchio

Paolo Manzoni

Antonio Boldrini

Piermichele Paolillo

Sandra Di Fabio

Luigi Orfeo

Mauro Stronati

Costantino Romagnoli

Affiliations

Soon will be listed here.

Abstract

Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease. Prevention of bronchiolitis strongly relies on the adoption of environment and the hygienic behavior measures; an additional prophylactic effect may be offered, in selected cases, by Palivizumab, a humanized monoclonal antibody produced by recombinant DNA technology, able to prevent RSV infection by blocking viral replication.After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection.

Citing Articles

Respiratory Syncytial Virus Burden in Premature Infants: The Role of Season With and Without RSV Immunoprophylaxis in a Multicenter Study.

Domany K, Mandelberg A, Burrack N, Golan-Tripto I, Masarweh K, Gur M Pediatr Pulmonol. 2025; 60(3):e71022.

PMID: 40042149 PMC: 11881211. DOI: 10.1002/ppul.71022.

Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development.

Babawale P, Martinez-Espinoza I, Mitchell A, Guerrero-Plata A Pathogens. 2025; 14(2).

PMID: 40005481 PMC: 11858734. DOI: 10.3390/pathogens14020104.

Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection.

Manti S, Baraldi E Ital J Pediatr. 2025; 51(1):26.

PMID: 39905524 PMC: 11796128. DOI: 10.1186/s13052-025-01844-9.

Exploring the adoption of less restricted criteria for respiratory syncytial virus prophylaxis in late preterm infants: insights from a retrospective analysis.

Mondi V, Paolillo P, Bedetta M, Lucangeli N, Picone S Front Pediatr. 2023; 11:1154518.

PMID: 37360357 PMC: 10285389. DOI: 10.3389/fped.2023.1154518.

Hospitalization for bronchiolitis in children aged ≤ 1year, Southern Italy, year 2021: need for new preventive strategies?.

Baldassarre M, Loconsole D, Centrone F, Caselli D, Martire B, Quartulli L Ital J Pediatr. 2023; 49(1):66.

PMID: 37280662 PMC: 10243233. DOI: 10.1186/s13052-023-01455-2.

References

Gaboli M, Asensio de la Cruz O, de Aguero M, Moreno-Galdo A, Perez G, Sanchez-Solis de Querol M . Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study. Pediatr Pulmonol. 2013; 49(5):490-502. DOI: 10.1002/ppul.22826. View

Boyce T, Mellen B, Mitchel Jr E, Wright P, Griffin M . Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000; 137(6):865-70. DOI: 10.1067/mpd.2000.110531. View

Figueras Aloy J, Carbonell Estrany X . [Update of recommendations on the use of palivizumab as prophylaxis in RSV infections]. An Pediatr (Barc). 2014; 82(3):199.e1-2. DOI: 10.1016/j.anpedi.2014.10.004. View

van den Hout L, Sluiter I, Gischler S, de Klein A, Rottier R, IJsselstijn H . Can we improve outcome of congenital diaphragmatic hernia?. Pediatr Surg Int. 2009; 25(9):733-43. PMC: 2734260. DOI: 10.1007/s00383-009-2425-8. View

Paes B, Mitchell I, Li A, Lanctot K . Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr. 2011; 171(5):833-41. PMC: 3327836. DOI: 10.1007/s00431-011-1654-8. View

Welliver Sr R, Checchia P, Bauman J, Fernandes A, Mahadevia P, Hall C . Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin. 2010; 26(9):2175-81. DOI: 10.1185/03007995.2010.505126. View

Andabaka T, Nickerson J, Rojas-Reyes M, Rueda J, Vrca V, Barsic B . Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013; (4):CD006602. DOI: 10.1002/14651858.CD006602.pub4. View

Hall C, Weinberg G, Iwane M, Blumkin A, Edwards K, Staat M . The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009; 360(6):588-98. PMC: 4829966. DOI: 10.1056/NEJMoa0804877. View

Hall C, Weinberg G, Blumkin A, Edwards K, Staat M, Schultz A . Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013; 132(2):e341-8. DOI: 10.1542/peds.2013-0303. View

10.

. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009; 124(6):1694-701. DOI: 10.1542/peds.2009-2345. View

11.

Medici M, Arcangeletti M, Rossi G, Lanari M, Merolla R, di Luzio Paparatti U . Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the "Osservatorio VRS" Study (2000-2004). New Microbiol. 2006; 29(1):35-43. View

12.

Stevens T, Sinkin R, Hall C, Maniscalco W, McConnochie K . Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000; 154(1):55-61. View

13.

Paes B, Mitchell I, Yi H, Li A, Lanctot K . Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J. 2013; 33(2):e29-33. DOI: 10.1097/INF.0000000000000019. View

14.

. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014; 134(2):e620-38. DOI: 10.1542/peds.2014-1666. View

15.

Subramanian K, Weisman L, Rhodes T, Ariagno R, Sanchez P, Steichen J . Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998; 17(2):110-5. DOI: 10.1097/00006454-199802000-00006. View

16.

van Beek D, Paes B, Bont L . Increased risk of RSV infection in children with Down's syndrome: clinical implementation of prophylaxis in the European Union. Clin Dev Immunol. 2013; 2013:801581. PMC: 3708408. DOI: 10.1155/2013/801581. View

17.

Ambrose C . Severe RSV disease in preterm infants born at 29 to 35 weeks' gestation in the United States. Pediatrics. 2014; 134(6):e1781. DOI: 10.1542/peds.2014-2901A. View

18.

Jones L, Hashim A, McKeever T, Cook D, Britton J, Leonardi-Bee J . Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. Respir Res. 2011; 12:5. PMC: 3022703. DOI: 10.1186/1465-9921-12-5. View

19.

Collins P, Melero J . Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011; 162(1-2):80-99. PMC: 3221877. DOI: 10.1016/j.virusres.2011.09.020. View

20.

Blanken M, Koffijberg H, Nibbelke E, Rovers M, Bont L . Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One. 2013; 8(3):e59161. PMC: 3595233. DOI: 10.1371/journal.pone.0059161. View